Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects With Gout and Mild to Moderate Chronic Kidney Disease

NCT04987294 is registered in ClinicalTrials.gov with Allena Pharmaceuticals as lead sponsor.

NCT NCT04987294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04987294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects With Gout and Mild to Moderate Chronic Kidney Disease
Lead sponsor
Allena Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
September 2, 2022
Completion date
September 2, 2022
Enrollment
19 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases, gout, hyperuricemia